利格列汀与格列美脲对2型糖尿病患者认知功能影响的随机双盲对照研究
CAROLINA-COGNITION研究是CAROLINA试验的子研究,评估利格列汀与格列美脲对2型糖尿病伴心血管高风险患者加速认知衰退的影响。共纳入3163例患者,中位随访6.1年,两组加速认知衰退发生率无显著差异(27.8% vs 27.6%,OR 1.01,95%CI 0.86-1.18)。
要点
- 利格列汀与格列美脲在6.1年随访中加速认知衰退风险相似。
- 第160周时两组加速认知衰退风险亦无差异(OR 1.07,95%CI 0.91-1.25)。
- 亚组分析及绝对认知变化均未显示组间差异。
核心结论
- 在相对早期2型糖尿病伴心血管高风险人群中,利格列汀与格列美脲治疗6.1年加速认知衰退风险无差异。
研究设计与样本
- CAROLINA-COGNITION是随机、双盲、活性对照的CAROLINA试验子研究,纳入年龄≥40且≤85岁、HbA1c 48-69 mmol/mol(6.5-8.5%)的2型糖尿病患者,排除胰岛素治疗。
- 共3163例参与者构成认知队列,来自医院和基层站点,1:1随机分配至利格列汀或格列美脲,按中心分层。
主要发现
- 中位随访6.1年,加速认知衰退发生率利格列汀组27.8%(449/1618),格列美脲组27.6%(426/1545),OR 1.01(95%CI 0.86,1.18)。
- 第160周时加速认知衰退OR 1.07(95%CI 0.91,1.25)。
- 预设亚组(性别、年龄、种族、民族、抑郁症状、心血管风险、糖尿病病程、白蛋白尿)及绝对认知变化均无组间差异。
关键数值与推荐
- 主要认知结局为随访结束时加速认知衰退的发生,定义为基线MMSE≥24的参与者中MMSE或注意力与执行功能复合测量回归指数评分≤第16百分位。
临床怎么用
- 对于2型糖尿病伴心血管高风险患者,选择利格列汀或格列美脲时无需因认知功能获益差异而偏好某一药物。
局限性
- 研究由勃林格殷格翰赞助。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Type 2 diabetes, particularly with concomitant CVD, is associated with an increased risk of cognitive impairment. We assessed the effect on accelerated cognitive decline (ACD) of the DPP-4 inhibitor linagliptin vs the sulfonylurea glimepiride in individuals with type 2 diabetes. METHODS: The CAROLINA-COGNITION study was part of the randomised, double-blind, active-controlled CAROLINA trial that evaluated the cardiovascular safety of linagliptin vs glimepiride in individuals with age ≥40 and ≤85 years and HbA1c 48-69 mmol/mol (6.5-8.5%) receiving standard care, excluding insulin therapy. Participants were randomised 1:1 using an interactive telephone- and web-based system and treatment assignment was determined by a computer-generated random sequence with stratification by center. The primary cognitive outcome was occurrence of ACD at end of follow-up, defined as a regression-based index score ≤16th percentile on either the Mini-Mental State Examination (MMSE) or a composite measure of attention and executive functioning, in participants with a baseline MMSE score ≥24. Prespecified additional analyses included effects on ACD at week 160, in subgroups (sex, age, race, ethnicity, depressive symptoms, cardiovascular risk, duration of type 2 diabetes, albuminuria), and absolute changes in cognitive performance. Participants, caregivers, and people involved in measurements, examinations or adjudication, were all masked to treatment assignment. RESULTS: Of 6033 participants recruited from hospital and primary care sites, 3163 (38.0% female, mean age/diabetes duration 64/7.6 years, MMSE score 28.5, HbA1c 54 mmol/mol [7.1%]) represent the CAROLINA-COGNITION cohort. Over median 6.1 years, ACD occurred in 27.8% (449/1618, linagliptin) vs 27.6% (426/1545, glimepiride), OR 1.01 (95% CI 0.86, 1.18). Also, no differences in ACD were observed at week 160 (OR 1.07 [0.91, 1.25]), between treatments across subgroups, or for absolute cognitive changes. CONCLUSIONS/INTERPRETATION: In a large, international outcome trial in people with relatively early type 2 diabetes at elevated cardiovascular risk, no difference in risk for ACD was observed between linagliptin and glimepiride over 6.1 years. FUNDING: This study was sponsored by Boehringer Ingelheim. TRIAL REGISTRATION: ClinicalTrials.gov NCT01243424.
引用
- Biessels GJ, Verhagen C, Janssen J, et al. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia. 2021. PMID: 33559704. doi:10.1007/s00125-021-05393-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。